You have PCOS and you started tirzepatide through a telehealth service. For a while, the scale moved. Then it stopped. The service replied the way it always had, with a message about the next dose. Nobody ordered blood work. Nobody explained why the medication might have stopped working for you. When you searched for answers to a tirzepatide plateau with PCOS, you found programs that look like the one you already have. A fair question came with the search. Is any of this legal? Is a licensed clinician on the other end of the screen?
This page answers that question for GoodLife Health and gives you a way to answer it for any service you are weighing. It also says plainly who should not join, so a reader who wants the next dose by Friday can leave before the checkout. GoodLife Health finds the reason before raising the dose. For a tirzepatide plateau with PCOS, that means a clinician reads fasting insulin and thyroid together, with A1C and the lipid markers beside them, before deciding whether the dose should change at all. GoodLife Health is a clinician-led membership at $299 a month, available in all 50 states.
- A plateau on tirzepatide is a question for the labs before it is a reason to raise the dose.
- GoodLife Health finds the reason before raising the dose and reads fasting insulin and thyroid together.
- Online care is legal when a clinician licensed in your state prescribes FDA-approved medication that a pharmacy dispenses.
- Clinicians licensed in all 50 states review every patient and can decline to accept one.
- The $598 sign-up hold is released if you are not accepted and is charged, non-refundable, once you are.
- This membership is the wrong choice for anyone who wants a higher dose without blood work.
The dose went up and the question never did
The pattern is easy to describe and hard to live with. The first months on tirzepatide went well enough that you trusted the plan. Then the loss slowed and stopped. The service sent a message about moving up a dose. You moved up. For a few weeks, something shifted again. Then it stalled. The next message arrived. Each time, the answer was the same.
At no point did anyone order a blood test. Nobody asked whether your fasting insulin had ever been drawn, when your thyroid was last checked or how PCOS had been handled before you arrived. The intake form asked whether you qualified for the prescription. It asked nothing about why your body might be responding the way it is.
If you have lived with PCOS for some years, this rhythm may be familiar. One clinician may have offered the pill. Another may have told you to eat fewer carbs. The telehealth prescriber offered a higher dose. Each answer came quickly. None came with a test that explained anything. None came with a clinician who stayed long enough to see whether it worked.
So when you started looking at other options, the doubt came with you. You may have read the news about compounded GLP-1 medication. You may not be sure whether what you were sent was branded or compounded. You may never have seen your prescriber's face or learned a name. It is reasonable to ask whether an online clinic is operating within the law. It is just as reasonable to ask whether the person approving each increase is a licensed clinician who has read your chart or a signature at the end of a form.
That doubt is useful, so keep it. Apply it to us as hard as you apply it to anyone. It is the same doubt that should have been applied to every dose increase so far.
What is going on when the dose is the only answer
Why the dose keeps going up
Most telehealth weight-loss services route a patient through an intake form to whichever provider is available. When a service earns money on the drug, it has a structural reason to keep you on the highest dose you can tolerate. That does not make every prescriber careless. It does mean the business and the clinical question can pull in different directions. When a plateau arrives, the simplest response for that model is the next dose. Finding the reason takes blood work, a clinician's time and a conversation. A price built around a prescription does not pay for them.
When the only answer to a plateau is a higher dose, nobody has asked the question yet.
What a plateau asks for
We do not know why your weight stopped moving. Nobody can know that before results are on the table. A plateau can have more than one explanation. The dose is one variable among several. Raising it tests only one possible answer.
For a plateau with PCOS, GoodLife Health reads fasting insulin and thyroid together. The panel measures fasting insulin so that insulin resistance can be seen before glucose turns abnormal. Thyroid function is drawn as TSH With Reflex To Free T4. A1C sits beside them, along with the lipid panel and ApoB. None of these results decides your treatment on its own. Read together by a clinician who knows your history, they give a reason to change the dose, a reason to hold it or a question to ask next.
Medicine is moving toward this order of work. In September 2026, Lilly listed its own self-pay prices for Zepbound vials on LillyDirect, from $299 to $449 a month depending on dose. NovoCare published its own self-pay prices for Wegovy the same month. When the manufacturer publishes the price of the drug, a clinic no longer needs to fold that price into its fee. It can charge for the clinical work and leave the drug to the pharmacy.
What legal looks like
Legal online care has three parts you can check. The clinician holds a license that allows them to treat a patient in your state. The medication is approved by the FDA. A pharmacy dispenses it.
GoodLife Health is operated by GoodLife Health Professional Corporation, an Arizona professional corporation. Its clinicians are licensed in all 50 states. They practice independently in Arizona and California and with collaborating physicians elsewhere. A clinician's license carries the responsibility for what that clinician prescribes. The full structure is set out in What Is GoodLife Health?
We prescribe branded, FDA-approved medication only. For tirzepatide, that means Zepbound or Mounjaro, when a clinician judges one indicated. We never prescribe compounded GLP-1. The FDA has published its concerns about unapproved GLP-1 drugs used for weight loss. The manufacturers have gone to court over compounded copies of their drugs. Neither fact tells you what is in your current supply. If you want to know, the label names the product and the pharmacy that filled it.
GoodLife Health does not dispense, compound or take title to medication. Your prescription goes to the pharmacy you choose, which fills it at its own price and bills you directly. GoodLife Health sets nothing, sees nothing and takes nothing on it.
What real looks like
A real clinician can say no. A clinician reviews every patient before accepting one. Some are not accepted. When that happens, the $598 hold on the card is released and the patient is never charged. Once a patient is accepted, the first two months are charged and are non-refundable. An app that approves everyone does not have to look at anyone.
The clinician who accepts you stays. That clinician orders your panel, reads it with you over video and answers by message between visits. The medical director is a Doctor of Nursing Practice and a board-certified family nurse practitioner. Every clinical protocol on the platform is reviewed under her direction.
Cassandra, the software behind the portal, organizes intake and surfaces trends in your results. She supports the clinician. She does not diagnose or prescribe. A person with a license makes every clinical decision.
You can check all of this yourself. Ask for your clinician's name and license number. Then look the license up on the licensing board's website for your state. Do the same for the prescriber who has been raising your dose.
What the membership does and what it costs
GoodLife Health is precision direct primary care for cardiometabolic optimization. For a plateau, the order of work is fixed. The panel is drawn first. A clinician reads it with you. Then the clinician decides what, if anything, should change. Put plainly, GoodLife Health finds the reason before raising the dose.
The first panel includes Fasting Insulin, Hemoglobin A1c (HbA1c), TSH With Reflex To Free T4, Lipid Panel, Standard, Apolipoprotein B (ApoB), Lipoprotein (A) and Hs-CRP. It repeats every 90 days, so you see the same markers four times a year. Every result is in your hands. If you come from another prescriber, the clinician reviews your current dose and decides with you what happens next. The decision follows the results. What a Direct Primary Care Visit Actually Looks Like walks through a visit from the first lab draw to the quarterly review.
The fee is the same whatever medication is indicated and whatever the dose. It is the same for Zepbound or Mounjaro, at the lowest dose and the highest. There is no molecule upcharge and no dose upcharge, so the practice earns nothing more when your dose goes up. That is Medication-Neutral Pricing. It means a clinician here has no stake in the next escalation.
A change in dose is decided after fasting insulin, A1C and thyroid results are read together. The panel informs that decision and cannot promise what the results will show.
Here is the offer in full. The membership is $299 a month. At sign-up, $598 is held on your card to cover the first two months. It is a hold, charged only once a clinician accepts you into care. If the clinician cannot accept you, the hold is released and you are never charged. Once you are accepted, the first two months are charged and are non-refundable. From month three, the membership is month to month. The membership is $3,588 a year. The fee buys four cardiometabolic lab panels a year, every result in your hands, a clinician who stays, video visits and messaging with the care team between visits. Medication, when it is indicated, is prescribed to the pharmacy you choose at that pharmacy's price. That pharmacy bills you. Its own return and refund policy applies.
What the membership does not do matters as much. It does not promise weight loss, typical or otherwise. It does not promise that the plateau will break. It does not promise that insurance will cover Zepbound or Mounjaro. Whether a plan covers a medication is between you, the plan and the pharmacy. Prior authorization is the pharmacy's process. We do not claim to run it, speed it or win it. The membership pairs with your insurance, which stays in place for catastrophic coverage. Its scope is cardiometabolic care, so keep your insurance and the doctors it pays for.
The plain answer to your question
Yes, this is legal care. The clinicians are real. A licensed clinician in your state reviews you, can decline you, prescribes only FDA-approved medication when it is indicated and sends it to the pharmacy you choose. You can verify the license yourself before you pay anything.
GoodLife Health sits between the $20,000-a-year concierge practice and the $99-a-month compounded app. We say so openly. The app will cost you less each month and we will not argue with that. The difference is what each model earns from. We earn the membership and nothing on what is prescribed, so the dose follows your results.
What the membership returns is the work nobody has done yet: a diagnosis drawn from your own markers, the same markers followed every 90 days and no more dose decisions made without results. We test first and treat second. We sell neither the drug nor the dose. The reason to start now is in your inbox. The next escalation message will arrive whether you answer it or not. If your dose is going to change, the time to draw fasting insulin and thyroid is before that change, while the plateau is still a question.
Whatever you decide, you can do three things this week. Ask your current prescriber whether your fasting insulin has ever been measured. Ask when your thyroid was last checked. Ask what the reason is for the next increase and what result would show it is working. Then look up your prescriber's license. If the answers are thin, you will know more than you did, whether or not you ever join us.
Who this is not for
If any of what follows describes you, leave here. Leaving now costs you nothing.
This membership is not for anyone who wants the next dose this week without blood work. A clinician here will want results before changing anything. That takes time you may not want to spend.
It is not for anyone who wants compounded tirzepatide. We do not prescribe compounded GLP-1 at any price. If that is what you want, the $99 app exists for it.
It is not for anyone who needs a promise. No clinician can honestly promise that a plateau will break or that weight will come off at a certain rate. We will not make that promise either.
It is not for anyone who needs the medication covered by insurance before starting. Coverage is between you, your plan and your pharmacy. We cannot change that answer.
It is not for anyone who cannot commit two months before deciding. If a clinician cannot accept you, the $598 hold is released and you are never charged. Once you are accepted, the first two months are charged and are non-refundable. Join only if two months of testing and follow-up is something you want.
It does not replace in-person care or your insurance. Our scope is cardiometabolic health. If you need a broader primary care practice, keep the one you have.
It is for you if you want the plateau explained before the dose moves. It is for you if you want to know who your clinician is, read your own results and keep the same person reading them every quarter. If that is the care you have been looking for, the check below is the first step.
Related Reading
- What Is GoodLife Health? Direct Primary Care, Explained (2026)
- What a Direct Primary Care Visit Actually Looks Like (2026)
References
- Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings
- NovoCare Pharmacy — Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss